Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer.
Status In progress
Process STA 2018
ID number 1574

Provisional Schedule

Committee meeting: 1 05 October 2021
Expected publication 15 December 2021

Project Team

Project lead Thomas Fiest

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Key events during the development of the guidance:

Date Update
05 February 2021 Invitation to participate
22 October 2020 - 19 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 February 2020 Please note that following on from advice received from the company this appraisal has now been scheduled into the work programme We anticipate that the appraisal will begin during early February 2021 when we will write to you about how you can get involved.
17 October 2019 In progress. Refered 05/12/2017
30 August 2019 Suspended. To appraise the clinical and cost-effectiveness of atezolizumab in combination with nab-paclitaxel and chemotherapy within its marketing authorisation for breast cancer.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance